CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 12.38: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.25%Below 5Y avg (0.44%)
Annual Rate
CNY 0.04Paid annual
Payout Ratio
42.3%Sustainable
Last Ex-Dividend
Sep 4, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.79BCNY863.67M · vs all stocks (USD)
Trailing P/E
76.50xRevenue (TTM)
798.78MCNY119.19M · vs all stocks (USD)
Profit Margin
9.28%Beta
-0.1950xvs all stocks
52-Week Change
-16.96%vs all stocks
Market Capitalization
5.79BCNY863.67M · vs all stocks (USD)
Enterprise Value
5.04BCNY751.35M · vs all stocks (USD)
Trailing P/E
76.50xPrice to Sales (TTM)
7.20xPrice to Book (MRQ)
3.31xEnterprise to Revenue
6.30xEnterprise to EBITDA
34.53xGross Margin
58.56%Profit Margin
9.28%Operating Margin
13.26%Return on Assets (TTM)
1.72%Return on Equity (TTM)
3.41%Revenue (TTM)
798.78MCNY119.19M · vs all stocks (USD)
Revenue per Share (TTM)
1.91CNYUpdated Sep 19, 2026Quarterly Revenue Growth
-0.60%Gross Profit (TTM)
458.32MCNY68.39M · vs all stocks (USD)
EBITDA (TTM)
155.97MCNY23.27M · vs all stocks (USD)
Net Income (TTM)
74.12MCNY11.06M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
122.10%Operating Cash Flow (TTM)
89.38MCNY13.34M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
54.29MCNY8.10M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0350CNYUpdated Sep 19, 2026Trailing Annual Dividend Yield
0.25%vs all stocks
5-Year Average Dividend Yield
0.44%vs all stocks
Payout Ratio
42.25%Minority Interest (Equity)
15.87MCNYFY2025 · Dec 31, 2025Revenue
827.14MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
352.47MCNYFY2025 · Dec 31, 2025Gross Profit
474.67MCNYFY2025 · Dec 31, 2025Operating Income
69.62MCNY10.39M · vs all stocks (USD)
Pre-tax Income
77.46MCNYFY2025 · Dec 31, 2025Income Tax Expense
22.25MCNYFY2025 · Dec 31, 2025Net Income
55.21MCNYFY2025 · Dec 31, 2025EBIT
77.60MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
155.97MCNYFY2025 · Dec 31, 2025Research & Development
89.76MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
193.71MCNYFY2025 · Dec 31, 2025Other Operating Expenses
13.26MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
6.51MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
139.71KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1559CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1559CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
417.49MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
417.49MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
55.21MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
9.88MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-26.96MCNYFY2025 · Dec 31, 2025Free Cash Flow
-34.96MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
274.34MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
55.21MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-1.01MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-79.84MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.32MCNYFY2025 · Dec 31, 2025Capital Expenditures
-8.00MCNYFY2025 · Dec 31, 2025Purchase of Investments
-840.00MCNYFY2025 · Dec 31, 2025Sale of Investments
650.07MCNYFY2025 · Dec 31, 2025Other Investing Activity
-6.69MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-204.62MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-35.50MCNYFY2025 · Dec 31, 2025Other Financing Charges
-4.25MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-39.74MCNYFY2025 · Dec 31, 2025Shares Outstanding
417.60MSharesUpdated Sep 19, 2026Float Shares
126.42MSharesUpdated Sep 19, 2026% Held by Insiders
70.76%vs all stocks
% Held by Institutions
1.93%vs all stocks
Total Cash (MRQ)
647.98MCNY96.69M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.55CNYUpdated Sep 19, 2026Total Debt (MRQ)
3.40MCNY506.72K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0019xCurrent Ratio (MRQ)
4.65xBook Value per Share (MRQ)
4.16CNYUpdated Sep 19, 2026Total Assets
2.03BCNY302.49M · vs all stocks (USD)
Total Current Assets
1.13BCNYFY2025 · Dec 31, 2025Total Liabilities
319.97MCNYFY2025 · Dec 31, 2025Total Non-current Assets
898.32MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
55.53MCNYFY2025 · Dec 31, 2025Total Current Liabilities
264.44MCNYFY2025 · Dec 31, 2025Cash
274.31MCNYFY2025 · Dec 31, 2025Cash Equivalents
30.58KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
274.34MCNYFY2025 · Dec 31, 2025Other Short-term Investments
351.22MCNYFY2025 · Dec 31, 2025Accounts Receivable
185.22MCNYFY2025 · Dec 31, 2025Inventory
139.03MCNYFY2025 · Dec 31, 2025Accounts Payable
69.56MCNYFY2025 · Dec 31, 2025Short-term Debt
38.79MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.56MCNYFY2025 · Dec 31, 2025Long-term Debt
3.00MCNYFY2025 · Dec 31, 2025Common Stock (Book)
417.60MCNYFY2025 · Dec 31, 2025Retained Earnings
701.77MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.71BCNY254.75M · vs all stocks (USD)
52-Week Low
11.42CNYUpdated Sep 19, 202652-Week High
18.47CNYUpdated Sep 19, 202652-Week Change
-16.96%vs all stocks
Beta
-0.1950xvs all stocks
50-Day MA
14.03CNYUpdated Sep 19, 2026200-Day MA
14.08CNYUpdated Sep 19, 2026Avg 10-Day Volume
8.51MSharesUpdated Sep 19, 2026Avg 30-Day Volume
16.57MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
0.1800CNYUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 12.38: safe zoneNotable
Altman Z-Score: 12.38
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing SL Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Keqian Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shouyao Holdings Beijing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kuros Biosciences AG
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
L&C Bio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk